Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions

The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Jeffrey Vietri, James Harnett, Birol Emir, Erica Chilson
Materialtyp:	Artikel
Språk:	English
Publicerad:	Taylor & Francis Group 2020-01-01
Serie:	Human Vaccines & Immunotherapeutics
Ämnen:	13-valent pneumococcal vaccine pneumococcal conjugate vaccine pcv13 pneumococcal disease pneumococcal vaccines immunization risk factors
Länkar:	http://dx.doi.org/10.1080/21645515.2019.1632683

Liknande verk

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
av: Strutton David R, et al.
Publicerad: (2012-08-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
av: M. V. Fedoseenko, et al.
Publicerad: (2014-09-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
av: Germaine Hanquet, et al.
Publicerad: (2022-01-01)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
av: John M. McLaughlin, et al.
Publicerad: (2019-04-01)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
av: Hyunju Lee, et al.
Publicerad: (2014-02-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
av: Giske Biesbroek, et al.
Publicerad: (2014-02-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
av: Kristiana Alexandrova Nikolova, et al.
Publicerad: (2021-10-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
av: Mikkelsen Malene B, et al.
Publicerad: (2023-08-01)

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
av: Starla Hayward, et al.
Publicerad: (2016-04-01)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
av: George Gourzoulidis, et al.
Publicerad: (2023-09-01)

Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden
av: Karin Bergman, et al.
Publicerad: (2021-08-01)

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
av: Wenjuan Wang, et al.
Publicerad: (2022-01-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
av: Thundon Ngamprasertchai, et al.
Publicerad: (2023-06-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
av: A. V. Rudakova, et al.
Publicerad: (2014-01-01)

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
av: Yan Li, et al.
Publicerad: (2021-11-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
av: Ching-Fen Shen, et al.
Publicerad: (2021-09-01)

Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
av: Stephanie Perniciaro, et al.
Publicerad: (2021-08-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
av: Deborah Lehmann, et al.
Publicerad: (2017-12-01)

Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
av: Arijita Deb, et al.
Publicerad: (2022-09-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
av: N. L. Chernaya, et al.
Publicerad: (2012-02-01)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
av: Erica Chilson, et al.
Publicerad: (2020-11-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
av: Sophie Warren, et al.
Publicerad: (2023-08-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
av: Earnshaw Stephanie R, et al.
Publicerad: (2012-04-01)

Results of immunoprophylaxis of HIV-infected patients with 13-valent conjugated pneumococcal vaccine
av: Alexander V. Zhestkov, et al.
Publicerad: (2021-11-01)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
av: Mirjam J. Knol, et al.
Publicerad: (2015-11-01)

IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India
av: Chythra R. Rao, et al.
Publicerad: (2024-12-01)

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
av: Johnna Perdrizet, et al.
Publicerad: (2023-04-01)

Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
av: A. V. Rudakova, et al.
Publicerad: (2014-09-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
av: Ralf Rene Reinert, et al.
Publicerad: (2012-06-01)

Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017
av: Satoshi Nakano, et al.
Publicerad: (2020-11-01)

Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018
av: Ashleigh McGirr, et al.
Publicerad: (2018-11-01)

Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trialResearch in context
av: Heidi Smith-Vaughan, et al.
Publicerad: (2023-03-01)

Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
av: Xinren Che, et al.
Publicerad: (2023-05-01)

Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis
av: Hannah M.Garcia Garrido, et al.
Publicerad: (2020-12-01)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
av: Yu Hu, et al.
Publicerad: (2022-01-01)

Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
av: Melina Gade Sikjær, et al.
Publicerad: (2023-01-01)

Increased Invasive Pneumococcal Disease, North East England, UK
av: Catherine Houseman, et al.
Publicerad: (2017-01-01)

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
av: Michele Wilson, et al.
Publicerad: (2023-06-01)

Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
av: Sarah J. Pugh, et al.
Publicerad: (2018-12-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
av: Salil Bendre, et al.
Publicerad: (2024-02-01)